Analyst Alerts Archives - Page 29 of 37

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) Reiterated with ‘Buy’ Rating, $11 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $11 on Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) following the company’s recent presentation at the 2017 European Association for the Study of the Liver (EASL). The company presented two posters supporting further development of emricasan, showing that a reduction in MELD scores lowers risk of liver transplantation or death compared to patients with stable or increased MELD scores. The analyst noted that the posters signify that the continued development of emricasan is warranted. For more information, visit www.conatuspharma.com About Conatus Pharmaceuticals Conatus is a biotechnology company focused on the development…

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $41 PT on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR)

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $41 price target on the stock of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR). The report follows the company’s recent presentation of encouraging data for eptinezumab (formerly ALD403) at the 69th Annual American Academy of Neurology (AAN) meeting. Eptinezumab is currently in phase 3 clinical development for the prevention of chronic migraines. The Aegis analyst noted that this data suggests that increases in responder rates and reductions in HIT-6 scores for eptinezumab resulted in improved quality of life for those with chronic migraines. Additional data is expected to be released in the second…

WednesdayApr 26, 2017 11:19 am

NetworkNewsBreaks – Bollente Companies, Inc. (BOLC) Targets $17B Tankless Water Heater Industry

Bollente Companies (OTC: BOLC), through its trutankless division, is strengthening its lead in the tankless water heater industry with an award-winning, energy saving solution that addresses a multi-billion dollar demand. “Globally, tankless water heater sales generated an estimated revenue of nearly $17 billion, according to Persistence Market Research (http://nnw.fm/83kBA), and they are projected to exceed well over $25 billion by 2024. This market segment represents just a small part of the global green building sector, which is currently outpacing overall U.S. construction growth and continues to double in size every three years. Smart appliances, including IoT devices in the home,…

MondayApr 24, 2017 10:09 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Hold’ Rating, $2 PT on Intellipharmaceutics International, Inc. (NASDAQ: IPCI)

Aegis Capital has reiterated a ‘Hold’ rating and price target of $2 on shares of Intellipharmaceutics International (NASDAQ: IPCI). The company recently reported first quarter 2017 results with revenue of $1.2 million compared to $0.6 million in the same period of 2016. The increase in revenue is attributed to Focalin XR, per the company’s agreement with Par Pharmaceutical. The analyst expects the company to continue making progress throughout the year, with the recent launch of Par’s generic Focalin XR driving revenues. For more information, visit www.Intellipharmaceutics.com About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development…

FridayApr 21, 2017 11:42 am

NetworkNewsBreaks – Social Reality, Inc. (NASDAQ: SRAX) Enters $3.72 Million Securities Purchase Agreement

Internet advertising company Social Reality, Inc. (NASDAQ: SRAX) this morning announced its entry into a definitive securities purchase agreement with certain institutional and accredited investors for the purchase and sale of up to an aggregate of $3.72 million principal amount Secured Convertible Debentures and five year Series A Warrants representing the right to acquire up to 1,156,667 shares of the company’s Class A common stock in a transaction exempt from registration under the Securities Act of 1933. “This capital infusion satisfies certain current obligations, eliminates uncertainty of the variable priced financial instrument and provides us working capital to continue to…

FridayApr 21, 2017 11:15 am

NetworkNewsBreaks – Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) Prices $15M Public Offering

Adamis Pharmaceuticals (NASDAQ: ADMP) this morning priced its previously announced underwritten public offering of 4,285,715 shares of its common stock at $3.50 per share for gross proceeds of approximately $15 million. The offering is expected to close on April 26, 2017. Underwriters have an option to purchase up to 642,857 additional shares to cover over-allotments, if any. Adamis said it plans to use the proceeds for general corporate purposes. To view the full press release, visit: http://nnw.fm/bC094 About Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of…

WednesdayApr 19, 2017 8:57 am

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Reiterated with ‘Buy’ Rating, $3 PT at Aegis Capital

Aegis Capital Corp. has reiterated its ‘Buy’ rating and $3 price target on Ocera Therapeutics (NASDAQ: OCRX) following the company’s recent release of data from a preclinical model that suggests potential for OCR-002 as a treatment of Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH). The analyst noted this data, and OCR-002's potential as a treatment of Hepatic Encephalopathy (HE), as the sole reason for the reiterated ‘Buy’ rating. For more information, visit www.ocerainc.com About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations.…

WednesdayApr 19, 2017 8:55 am

NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Receives ‘Buy’ Rating, $11 PT at Aegis Capital

Aegis Capital Corp. recently issued a ‘Buy’ rating and price target of $11 on shares of ViewRay, Inc. (NASDAQ: VRAY). The action follows ViewRay’s recent agreement with CRG LP to amend the terms of its $50 million term loan agreement to expand the borrowing capacity to $65 million. The analyst noted this extension, as well as the company’s preliminary first-quarter results, which included two orders for the LINAC with gross proceeds of $12.3 million and three upgrades to installed Cobalt machines to LINACs for $5.8 million. The LINAC was approved in late February, and the analyst cited this as a major inflection point…

TuesdayApr 18, 2017 1:05 pm

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Reiterated with ‘Buy’ Rating, $14 PT at Aegis Capital

Trevena, Inc. (NASDAQ: TRVN) has been reiterated with a ‘Buy’ rating and $14 price target at Aegis Capital Corp., which noted that the commercial potential of the company’s Olinvo is “under-appreciated.” Olinvo differs from existing active drugs indicated for post-operative pain management by its mechanism of action, and it could be the first in a new class of molecules to receive FDA approval. The Aegis analyst noted that phase 3 read-outs demonstrated efficacy near the equivalent of morphine, as well as with improved side effect profiles, especially for respiratory depression and GI side effects. Aegis also estimated that Olinvo could generate…

TuesdayApr 18, 2017 8:15 am

NetworkNewsBreaks – Neurotrope, Inc. (NASDAQ: NTRP) Receives ‘Buy’ Rating, $31 PT at Aegis Capital

Aegis Capital Corp. recently issued a ‘Buy’ rating and price target of $31 on shares of Neurotrope, Inc. (NASDAQ: NTRP). The company has completed enrollment of its phase 2b clinical trial of Bryostatin-1 for the treatment of Alzheimer’s disease. The analyst noted that the company will be driven by the data from this trial, which is expected in late April. Based on expected sales of drugs that are intended to slow the decline in cognitive function or reduce symptoms, which have achieved market valuations in the $1 billion range after positive phase 2 data in the past, the analyst believes…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Breaks Categories: Analyst Alerts